REVIEW PAPER
Pharmacological profile and clinical features of cisplatin
| 1 | Department of Histology and Embryology, Medical University, Lublin, Poland |
| 2 | University Memory and Cognition Center, Cleveland, USA; Department of Neurodegenerative Diseases, Institute of Agricultural Medicine, Lublin, Poland |
CORRESPONDING AUTHOR
Katarzyna Gustaw-Rothenberg
Department of Neurodegenerative Diseases, Institute of Agricultural Medicine, Jaczewskiego 2, 20-950 Lublin, Poland.
Department of Neurodegenerative Diseases, Institute of Agricultural Medicine, Jaczewskiego 2, 20-950 Lublin, Poland.
J Pre Clin Clin Res. 2009;3(1):20–23
KEYWORDS
ABSTRACT
Cisplatin is currently one of the most widely used anticancer drugs in the world. The unlikely events surrounding the discovery of its anticancer activity, subsequent introduction into the clinic, and continuing research into platinum compounds is the subject of this review.
REFERENCES (38)
1.
Matsusaka S, Nagareda T, Yamasaki H: Does cisplatin (CDDP) function as a modulator of 5-fl uorouracil (5-FU) antitumor action? A study based on a clinical trial. Cancer Chemoth Pharm 2005, 55, 387-392.
2.
McEvoy GK (ed.): AHFS 2004 Drug Information. Bethesda, Maryland. American Society of Health-System Pharmacists, Inc., 2004, 929- 945.
3.
Meyer KB, Madias NE: Cisplatin nephrotoxicity. Miner Electrolyte Metab 1994, 20(4), 201-213.
4.
Farris FF, Dedrick RL, King FG: Cisplatin pharmacokinetics: applications of a physiological model. Toxicol Lett 1988, 43(1-3), 117-137. BC Cancer Agency Cancer Drug Manual Cisplatin Developed, September 1994 (limited revision March 2006).
5.
Pizzo P, Poplack D: Principles and Practice of Pediatric Oncology (4th ed.), Lippincott Williams & Wilkins, Philadelphia 2002, 256-259.
6.
National Institute for Occupational Safety and Health [NIOSH]: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings, NIOSH – Publications Dissemination, Cincinnati/Ohio, 25 Mach 2004, 71-83.
7.
Chabner BA, Longo DL: Cancer chemotherapy and biotherapy 3rd ed.), Lippincott, Williams & Wilkins, Philadelphia 2001, 453-459.
8.
Rosenberg B, Van Camp L, Krigas T: Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965, 205(4972), 698-699.
10.
Rebecca A, Alderden RA, Matthew D, Hall MD, Trevor W, Hambley T: The Discovery and Development of Cisplatin. J Chem Ed 2006, 83, 728-734.
11.
Go R, Adjel A: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999, 17(1), 409- 422.
12.
Nieto Y: DNA-binding agents. Cancer Chemother Biol Response Modif 2003, 21, Chapter 8.
13.
Cisplatin. USP DI. Volume 1. Drug information for the health care professional. 20th ed. Englewood, Colorado: Micromedex, Inc., 2002.
14.
Murry DJ: Comparative clinical pharmacology of cisplatin and carboplatin. Pharmacotherapy 1997, 17(5 Pt 2), 140-145.
15.
Crom WR, Glynn-Barnhart AM, Rodman JH, Teresi ME, Kavanagh RE, Christensen ML, Relling MV, Evans WE: Pharmacokinetics of anticancer drugs in children. Clin Pharmacokinet 1987, 12(3), 168- 213.
16.
O’Dwyer P, Stevenson J, Johnson S: Clinical Pharmacokinetics and Administration of Established Platinum Drugs. Drugs 2000, 59 (Suppl. 4), 19-27.
17.
Woollins D, Woollins A, Rosenberg B: The detection of trace amounts of trans-Pt(NH3)2Cl2 in the presence of cis-Pt(NH3)2Cl2. A high performance liquid chromatographic application of Kurnakov’s test”. Polyhedron 1983, 2(3), 175-178.
18.
Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sternson LA, Repta AJ: Pharmacokinetics of non-protein-bound platinum species following adminisration of cis-dichlorodiammineplatinum (II). Cancer Treat Rep 1979, 63(9-10), 1515-1521.
19.
Cisplatin Product Monograph, Mayne Pharma [Canada] Inc. 2003. Perry M, M.D. FACP: The Chemotherapy Source Book, Williams & Wilkins, Baltimore 1992, 405-409.
20.
Provincial Systemic Therapy Program Policy III-20: Prevention and management of extravasation of chemotherapy, BC Cancer Agency.
21.
Provincial Systemic Therapy Program, BC Cancer Agency, Vancouver, British Columbia, 1 February 2004.
22.
SCNAUSEA Protocol Summary: BC Cancer Agency, Vancouver, British Columbia: May 1999.
23.
Balis FM, Holcenberg JS, Bleyer WA: Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet 1983, 8, 202- 232.
24.
Trissel L: Handbook on Injectable Drugs (12th ed.), Bethesda MD, American Society of Health-System Pharmacists, 2003.
25.
Dorr RT, Von-Hoff DD: Drug monographs. In: Dorr R, Von-Hoff D (eds.): Cancer chemotherapy handbook (2nd ed.), Appleton and Lange, Norwalk, Connecticut 1994, 286-293.
26.
Basu R, Rajkumar A, Datta RN: Anaphylaxis to cisplatin following nine previous uncomplicated cycles. Int J Clin Oncol 2002, 7, 365-367.
27.
Wiernik P, Yeap B, Vogl SE, Kaplan BH, Comis RL, Falkson G, Davis TE, Fazzini E, Cheuvart B, Horton J: Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Invest 1992, 10(1), 1-9.
28.
BC Cancer Agency Head and Neck Tumour Group: BCCA Protocol summary for recurrent and metastatic nasopharyngeal cancer using cisplatin and etoposide [HNDE], BC Cancer Agency, Vancouver 2004.
29.
BC Cancer Agency Genitourinary Tumour Group: BCCA protocol summary for therapy for transitional cell cancers of the urothelium using methotrexate, vinblastine, doxorubicin and cisplatin [GUMVAC], BC Cancer Agency, Vancouver 2003.
30.
BC Cancer Agency Lung Tumour Group: BCCA protocol summary for combined chemotherapy and radiation treatment for stage 3 non-small cell lung cancer [LUCMT-1], BC Cancer Agency, Vancouver: 2005.
31.
BC Cancer Agency Gynecology Tumour Group: BCCA Protocol Summary for Treatment of Advanced/Recurrent Non-Small Cell Cancer of the Cervix with Cisplatin and Etoposide [GOCXADV], BC Cancer Agency, Vancouver 2000.
32.
BC Cancer Agency Genitourinary Tumour Group: BCCA protocol summary for combined modality therapy for sqamous cell cancer of the genitourinary system using fl uorouracil and cisplatin [GUFUP], BC Cancer Agency, Vancouver 2005.
33.
BC Cancer Agency Neuro-Oncology Tumour Group: BCCA Protocol Summary for adjuvant lomustine, cisplatin and vincristine in adult high-risk medulloblastoma or other primitive neuro-ectodermal tumour [PNET] – CNCCV, BC Cancer Agency, Vancouver 2002.
34.
BC Cancer Agency Gynecology Tumour Group: BCCA Protocol summary for treatment of high risk squamous cell carcinoma of cervix with concurrent cisplatin and radiation. [GOCXRADC], BC Cancer Agency, Vancouver 2002.
35.
BC Cancer Agency Genitourinary Tumour Group: BCCA protocol summary for therapy for locally advanced bladder cancer using concurrent cisplatin with radiation [GUBP], BC Cancer Agency, Vancouver 1999.
36.
BC Cancer Agency Head and Neck Tumour Group: BCCA Protocol summary for combined chemotherapy and radiation treatment for locally advanced squamous cell carcinoma of the head and neck [HNCMT2], BC Cancer Agency, Vancouver 2004.
37.
BC Cancer Agency Gastrointestinal Tumour Group: BCCA Protocol summary for combined modality therapy for locally advanced esophageal cancer using cisplatin, infusional fl uorouracil and radiation therapy. [GIEFUP], BC Cancer Agency, Vancouver 2000.
38.
International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Eng J Med 2004, 325(4), 351- 360.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.